Bayer's 2018 Financial Forecast Hit By Manufacturing Woes
Bayer's failure to comply with good manufacturing practice guidelines at a production site in Germany will impact supply of medicines in 2018, shaving millions from its financial forecast for the year ahead.
You may also be interested in...
Not for the first time this decade, the German major has been warned by the US FDA about its manufacturing processes and sorting out the problems could affect supplies of some big-selling products such as the blood pressure treatment Adalat and the erectile dysfunction drug Levitra.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.